Championing Science: If We Stop Hepatitis B From Spreading Related content Related video Oncternal Related article Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.
Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.
